$MRK News

Last published 2d ago

2d agoMRKMerck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 FibrosisBusiness WireRAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company’s Phase 2b clinical trial that evaluated the safety and efficacy of three doses of once-weekly, subcutaneous efinopegdutide (4 mg, 7 mg and 10 mg), an investigational injectable GLP-1/glucagon receptor co-agonist, versus place ...
5d agoMRNA MRKModerna raises 2026 outlook as CEO says newer vaccines are gaining tractionCNBCThe biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
1w agoGMAB ABBV MRK JNJ+4A little-known biotech’s high-stakes cancer bet just paid off and its shares doubledCNBCGenmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
1w agoMRKMerck & Co., Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoMRK LSEGMerck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strengthCNBCMerck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
1w agoMRKMerck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse PipelineBusiness WireSales Growth Reflects Continued Strength in Oncology and Animal Health, Plus Contributions From Other Products in Broader Portfolio, Including WINREVAIR Financial Highlights Total Worldwide Sales Were $18.1
2w agoENTX OGN MRKEntera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of DirectorsGlobeNewswireDr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE:OGN) He joins Entera with two decades of clinical development, regulatory execution, and
2w agoMRKKEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to ChemotherapyBusiness WireKEYNOTE-C93 showed median progression-free survival (PFS) was more than four times longer for these patients treated with KEYTRUDA as monotherapy (38.2 months) compared to platinum doublet chemotherapy (8.4
2w agoMRKSacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial CancerBusiness WireTroFuse-005 is the first and only global Phase 3 study of a TROP2 ADC to demonstrate improved overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in these patients who have received prior
2w agoHYFT MRNA MRK BNTXA Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better TargetsGlobeNewswireAUSTIN, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - An mRNA-based cancer therapy designed around each patient’s own tumor has delivered positive Phase 3 results. On October 22, Merck and
2w agoMRNA MRKDoctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fallCNBCSix melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma treatment.
2w agoMRK MRNAMerck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential SymposiumBusiness WireIntismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected stage IIB-IV
2w agoMRNA MRKModerna shares plunge after leak of partial cancer vaccine dataCNBCModerna's stock fell even though the full data, released later Thursday, appeared positive based on Wall Street expectations ahead of the release.
3w agoNTHI NBIX ACAD AVXL+1Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar MarketGlobeNewswireNEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brain cancer remains one of the hardest cancers to treat, and researchers are under pressure to find therapies that do more than slow the disease for a short time. For
3w agoMRKEuropean Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)Business WireFirst and only PD-1 inhibitor plus antibody-drug conjugate regimen approved in the European Union (EU) for patients with MIBC regardless of cisplatin eligibility Merck (NYSE:MRK), known as MSD outside of the United
3w agoNFLX CRWV .SPX .IXIC+8Wall Street's latest AI spook, Netflix layoffs, 'good debt' and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
4w agoMRK MRNAMerck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to makeCNBCHis comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia area.
4w agoMRKPaul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of DirectorsBusiness WireMerck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Paul J. Diaz, managing partner at Cressey & Company, will join the Company’s Board of
4w agoMRKMerck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026Business WireINTerpath-001 data to be presented in Presidential Symposium, featuring the first Phase 3 results for investigational intismeran autogene plus KEYTRUDA® (pembrolizumab), demonstrating improvements in recurrence-free
1mo agoMRKMerck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026Business WireRemigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at one year in patients with diabetic macular edema (DME) Remigromig is the first biologic with
1mo agoGOOGL META SHOP PYPL+4Google brings agentic AI to Gemini, starting with businessesTechCrunch
1mo agoNTHI MRNA MRK JNJ2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New HopeGlobeNewswireDENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of
1mo agoGILD SMMT AZN MRKAstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investmentCNBCPascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
1mo agoMRKMerck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29Business WireMerck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct.
1mo agoMRKMerck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)Business WireResults mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS Merck
1mo agoMRKMerck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) InhibitorBusiness WireMerck (NYSE:MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. ("SciBrunch"), today announced that they have entered into an exclusive global license agreement for
1mo agoTYO:4568 MRKIfinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily WithdrawnBusiness WireThe Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE:MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan
1mo agoMRKU.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)Business WireApproval based on results from the Phase 3 LITESPARK-011 trial evaluating WELIREG in combination with LENVIMA compared to cabozantinib for the treatment of patients with advanced ccRCC following treatment with a
1mo agoMRKMerck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular EdemaBusiness WireRemigromig demonstrated non-inferiority to active control ranibizumab for mean change from baseline in best-corrected visual acuity (BCVA) at week 52 Merck (NYSE:MRK), known as MSD outside of the United States and
1mo agoMRKU.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)Business WireIn HYPERION, in patients diagnosed with PAH in the last 12 months, adding WINREVAIR on top of background therapy reduced the risk of clinical worsening events compared to placebo, informing the use of WINREVAIR earlier
1mo agoMRKMerck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in JapanBusiness WireKEYTRUDA QLEX is the first and only subcutaneous immune checkpoint inhibitor in Japan that can be administered by a healthcare provider in as little as one minute Merck (NYSE:MRK), known as MSD outside of the United
1mo agoMRKMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)Business WireOpinion granted based on positive results from the Phase 3 KEYNOTE-B15 trial, which demonstrated improvements in event-free survival, overall survival and pathologic complete response rate If approved, KEYTRUDA plus
1mo agoMRKMerck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIVBusiness WireDebbie Allen, famed actress, director, producer and longtime HIV advocate, joins Merck to launch the initiative and honor the community Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today
1mo agoMRK MERCKCMorgan Stanley 24th Annual Global Healthcare Conference - MERCK & CO INCEarnings Call TranscriptsAll right. We're going to get started here. Thanks so much for joining us. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see the Morgan Stanley Research Disclosure website
1mo agoCATX MRKPerspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid TumorsGlobeNewswireSEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:CATX), a radiopharmaceutical development
2mo agoQNTM NVS MRK TGTX+1Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics MarketGlobeNewswireAUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the
2mo agoMRK MERCKCWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - MERCK & CO INCEarnings Call TranscriptsThank you for joining us for the afternoon session today. We have Team Merck with us. So with us, we have Carolyn Lishfield, the CFO of the company. We have Dean Lee, the head of R&D, president of Merck Research and ever
2mo agoMRKMerck to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceBusiness WireMerck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck
2mo agoMRKMerck to Participate in the Wells Fargo 21st Annual Healthcare ConferenceBusiness WireMerck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and
2mo ago.SPX AEM WBD BTC.CM+12August was the month of the comeback kids. Cramer reviews what drove the biggest winnersCNBCCNBC's Jim Cramer said August was a comeback month for stocks that had been battered by bearish narratives.
2mo agoUS30Y .SPX NVDA WMT+3The Treasury's debt buyback, Walmart earnings, Boise's AI boom and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
2mo agoMRNA MRK US30Y .SPX+6Target earnings, Canada tariffs, American Airlines' seatback screens and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
2mo agoMRK MRNAPersonalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trialCNBCThe combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
2mo agoMRK MRNAMerck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV MelanomaBusiness WireFirst and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The
3mo agoMRK GSKTrump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequencesCNBCDoctors and other experts say that splitting the measles, mumps and rubella shot has no scientific basis and is unlikely to get off the ground.
3mo agoMRKU.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second SeasonBusiness WireEMA also accepts application for the same population for ENFLONSIA based on results from the Phase 3 SMART trial If approved, children under two years of age at increased risk for severe RSV disease will be eligible
3mo agoMRKMerck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal chargesCNBCMerck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.
3mo agoMRKMerck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse PipelineBusiness WireSales Growth Reflects Continued Strength in Oncology, Including Initial Uptake of KEYTRUDA QLEX, and Animal Health, Plus Contributions From Launches Such as WINREVAIR Financial Highlights Total Worldwide Sales
3mo agoMRKMerck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 DevelopmentBusiness WireMulti-faceted strategy aims to enable rapid, broad and sustainable access to alimatravir (MK-8527), if approved, in low- and middle-income countries Voluntary licensing agreements cover 129 countries in regions which
3mo agoREGN MRKTessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive OfficerPR NewswireTessera Therapeutics ("Tessera"), the biotechnology company pioneering a new approach to genetic medicine known as Gene Writing™, today announced the ...